
Gilead Sciences (GILD) Stock Fell 2%, Remdesivir Shows Potential for Coronavirus Treatment
Remdesivir, Gilead Sciences’ experimental drug for patients with severe COVID-19 infection, showed promise in an early analysis, raising tentative hope that the first treatment for the novel virus may be on the horizon.